The last of the big 3 PBMs, which control upwards of 80% of US pharmacy benefit spending, has yielded to the competition. OptumRx will exclude Humira from some of its drug formulary offerings as of January 1, 2025. According to OptumRx, “Optum Rx will exclude Humira and prefer FDA-approved adalimumab biosimilars effective January 1, 2025 … Continue reading The Last Domino Falls: OptumRx to Exclude Humira® From Some Drug Formularies Beginning January 2025